@article{herrera garcia_2019, title={The Benefit and clinical characteristics after use of Nintedanib in Idiopathic Pulmonary Fibrosis: Benefit and clinical characteristics after use of Nintedanib in Idiopathic Pulmonary Fibrosis}, volume={2}, url={http://medicalreviews.info/index.php/jmr/article/view/24}, abstractNote={<p>SUMMARY</p> <p>Nintedanib is an approved antifibrotic agent for the treatment of idiopathic pulmonary fibrosis. (FPI) as monotherapy. To date, the evidence supports its effectiveness in this type of patients. We present a case of a Mexican patient of 69 years with Idiopathic Pulmonary Fibrosis (IPF) treated with nintedanib for 6 months as monotherapy in a university hospital. Before the 52 week period. There was a clear decrease in the patient’s forced vital capacity (FVC) from 70% (2.14L) to 60% (1.83L). The treatment with nintedanib was started for a period of 12 months at a dose of 150 mg VO every 12 hrs. Lung function stabilized increasing from 60% (1.83L) to 70% (2.14L), the treatment was well tolerated. Only with presence of mild adverse effects without repercussions.</p> <p> CONCLUSION</p> <p>We describe the successful case of a patient with Idiopathic Pulmonary Fibrosis after 52 weeks of treatment with Nintedanib, well tolerated and with improved lung function, until now the antifibrotic therapy represents a safe and therapeutically option as monotherapy.</p> <p> </p> <p> </p> <p> </p>}, number={4}, journal={Journal of Medical Reviews}, author={herrera garcia, jose C}, year={2019}, month={Apr.}, pages={Page No. : 283–285} }